Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

810 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-12-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single-arm, phase IV, open-label, prospective, non interventional study to evaluate the efficacy, tolerability and safety of rosuvastatin administered for 24 weeks in approximately 900 Greek subjects with hypercholesterolemia under normal clinical practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

NCT00654602

Dyslipidaemia

COMPLETED PHASE3

Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients

NCT00631189

Type IIa and IIb Hypercholesterolaemia

COMPLETED PHASE4

Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome

NCT00335699

Hypercholesterolemia

COMPLETED PHASE4

Evaluation of Crestor® (Rosuvastatin) in Daily Practice

NCT00837083

Hypercholesterolemia

COMPLETED

Registry On Efficacy and Safety Of Rosuvastatin, and Atorvastatin and Simvastatin In Hypercholesterolaemia

NCT01352897

Hypercholesterolaemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolaemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with hypercholesterolaemia who are already in treatment with rosuvastatin according to the approved SPC for no longer than 1 month prior to study entry
* Patients that are able to read, understand and sign the Patient Information \& Consent Form
* Patients that are willing to comply with all study requirements

Exclusion Criteria

* Patients that are likely not to comply with all study requirements
* Patients that currently participate or have participated in a 3 months period prior to study entry in another clinical trial
* Female of child bearing potential that do not use a reliable method of contraception. Pregnancy or lactation.
* Patients that meet any of the contraindications described in the approved SPC

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No